Polymorphism of tumor necrosis factor-α and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon-α therapy response

Human Immunology

Volumn 72, Issue 10, 2011, Pages 935-939

  Dogra, Gaurav ^a   Chakravarti, Anita ^a   Kar, Premashish ^a   Chawla, Yogesh Kumar ^b  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Hepatitis c virus; Interleukin 10; Polymorphism; Tumor necrosis factor alpha

Indexed keywords

INTERLEUKIN 10; PEGINTERFERON ALPHA2B; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INDIA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; BIOMARKERS, PHARMACOLOGICAL; CASE-CONTROL STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INDIA; INTERFERON-ALPHA; INTERLEUKIN-10; MIDDLE AGED; OUTPATIENTS; POLYETHYLENE GLYCOLS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; SEQUENCE ANALYSIS, DNA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80052964901     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2011.06.008     Document Type: Article

References (34)

1. Paladino N., Fainboim H., Theiler G., Schroder T., Muñoz A.E., Flores A.C., et al. Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism. J Virol 2006, 80:9144-9150.
2. Akkaya O., Kiyici M., Yilmaz Y., Ulukaya E., Yerci O. Clinical significance of activity of ALT enzyme in patients with hepatitis C virus. World J Gastroenterol 2007, 13:5481-5485.
3. Constantini P.K., Wawrzynowicz-Syczewska M., Clare M., Boron-Kaczmarska A., McFarlane I.G., Cramp M.E., et al. Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: An investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 2002, 22:404-412.
4. Höhler T., Kruger A., Gerken G., Schneider P.M., Meyer zum Büschenfelde K.H., Rittner C. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol 1998, 54:173-177.
5. Zein N.N., Germer J.J., El-Zayadi A.R., Pedro G., Vidigal Ethnic differences in polymorphisms of tumor necrosis factor-α, interleukin-10 and transforming growth factor-β1 genes in patients with chronic hepatitis C virus Infection. Am J Trop Med Hyg 2004, 70:434-437.
6. Minton Elizabeth J., David S., Paula S., Suzanne S., Mckendrick Michael W., Gleeson Dermot C., et al. Clearance of hepatitis C virus is not associated with single nucleotide polymorphisms in the IL-1, -6, or -10 genes. Hum Immunol 2005, 66:127-132.
7. Tzy-Yen C., Yih-Shou H., Wu Triang-Tiau, Yang Shun-Fa, Wu Chia-Jun, Tsay Gregory J., et al. Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. J Lab Clin Med 2007, 150:116-121.
8. Wang S., Wei M., Yi Han, Zhang K., Li He, Zhen Yang, et al. Roles of TNF-α gene polymorphisms in the occurrence and progress of SARS-Cov infection: A case-control study. BMC Infect Dis 2008, 8:27.
9. Govan V.A., Constant D., Hoffman M., Govan V.A., Constant D., Hoffman M., Williamson A.L. The allelic distribution of -308 tumor necrosis factor-alpha gene polymorphism in South African women with cervical cancer and control women. BMC Cancer 2006, 6:24.
10. Bidwell J., Keen L., Gallagher G., Kimberly R., Huizinga T., McDermott M.F., et al. Cytokine gene polymorphism in human disease: On-line databases. Genes Immun 1999, 1:3-19.
11. Nelson D.R., Lauwers G.Y., Lau J.Y.N., Davis G. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon non responders. Gasteroenterology 2000, 118:655-660.
12. Constantini P.K., Wawrzynowicz-Syczewska M., Clare M., Boron-Kaczmarska A., McFarlane I.G., Cramp M.E., et al. Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: An investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 2002, 22:404-412.
13. Thio C.L., Goedert J.J., Mosbruger T., Vlahov D.S., Strathdee A., et al. An analysis of tumor necrosis factor gene polymorphisms and haplotypes with natural clearance of hepatitis C virus infection. Genes Immun 2004, 5:294-300.
14. Lio D., Caruso C., Di Stefano R., Colonna Romano G., Ferraro D., Scola L., et al. Almasio; IL-10 and TNF-α polymorphisms and the recovery from HCV infection. Hum Immunol 2003, 64:674-680.
15. Mellor J., Holmes E.C., Jarvis L.M., Yap P.L., Simmonds P. Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: Implications for virus classification. The international HCV Collaborative Study Group. J Gen Virol 1995, 76:2493-2507.
16. Chinchai T., Labout J., Noppornpanth S., Theamboonlers A., Haggmans B.L., Osterhaus A.D., et al. Comparative study of different methods to genotype hepatitis C virus type 6 variants. J Virol Methods 2003, 109:195-201.
17. Knodell R.G., Ishak K.G., Black W.C., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic hepatitis. Hepatology 1981, 1:431-435.
18. Selzner N., McGilvray I. Can genetic variations predict HCV treatment outcomes?. J Hepatol 2008, 49:494-497.
19. Akkaya O., Kiyici M., Yilmaz Y., Ulukaya E., Yerci O. Clinical significance of activity of ALT enzyme in patients with hepatitis C virus. World J Gastroenterol 2007, 13:5481-5485.
20. Pavio Andmichael N., Lai M.C. The hepatitis C virus persistence: How to evade the immune system?. J Biosci 2003, 28:287-304.
21. Turner D.M., Williams D.M., Sankaran D., Lazarus M., Sinnott P.J., Hutchinson I.V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997, 24:1-8.
22. Anaya J.M., Correa P.A., Herrera M., Eskdale J., Gallagher G. Interleukin 10 (IL-10) influences autoimmune response in primary Sjögren's syndrome and is linked to IL-10 gene polymorphism. J Rheumatol 2002, 29:1874-1876.
23. Barrett S., Collins M., Kenny C., Ryan E., Keane C.O., Crowe J. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol 2003, 71:212-218.
24. Zaigham A., Tariq M., Akber H., Wasim J. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3. World J Gastroenterol 2005, 11:6656-6661.
25. Donaldson P.T., Clare M., Constantini P.K., Hadzic N., Mieli-Vergani G., Howard E., et al. HLA and cytokine gene polymorphisms in biliary atresia. Liver 2002, 22(3):213-219.
26. Chuang J.Y., Yang S.S., Lu Y.T., Hsieh Y.Y., Chen C.Y., Chang S.C., et al. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Dig Liver Dis 2009, 41:424-430.
27. Yee L.J., Tang J., Gibson A.W., Kimberly R., van Leeuwen D.J., Richard A., et al. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001, 33:708-712.
28. Mangia A., Santoro R., Piattelli M., Pazienza V., Grifa G., Iacobellis A., et al. IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection. Cytokines 2004, 25:103-109.
29. Knapp S., Branwen J.W., Hennig A.J., Frodsham, Zhang L., Hellier S., et al. Thomas1 and Mark R. Thursz1 interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003, 55(6):362-369.
30. Edwards-Smith C.J., Jonsson J.R., Purdie D.M., Bansal A., Shorthouse C., Elizabeth E.P., et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999, 30:526-530.
31. Dwards-Smith J., Hay J.L., Clouston A.D., Crawford D.H., Shorthouse C., Purdie D.M., et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000, 31:828-833.
32. Yee L.J., Tang J., Herrera J., Kaslow R.A., van Leeuwen D.J. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000, 1:386-390.
33. Rosen Hugo R., Mchutchison John G., Conrad Andrew J., Lentz Jennifer J.J., Gail M., Rose Steven L., et al. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol 2002, 97:714-720.
34. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.